Neuropeptide and Endocrine Signaling in CBS/PSP

📖 Wiki Page

therapeutic1473 wordssynced 2026-04-02

Neuropeptide and Endocrine Signaling in CBS/PSP

...

Neuropeptide and Endocrine Signaling in CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neuropeptide and Endocrine Signaling in CBS/PSP</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Solriamfetol</td>
<td>Dual DAT/SERT inhibitor, promotes wakefulness</td>
</tr>
<tr>
<td class="label">Pitolisant</td>
<td>Histamine H3 inverse agonist</td>
</tr>
<tr>
<td class="label">Orexin-A peptide</td>
<td>Direct receptor agonist</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">Solriamfetol</td>
<td>Additive hypertension risk</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">PYY (3-36)</td>
<td>Y2 agonist, appetite suppression</td>
</tr>
<tr>
<td class="label">NPY-based peptides</td>
<td>Y1/Y5 modulators</td>
</tr>
<tr>
<td class="label">Small molecule Y1 agonists</td>
<td>Neuroprotection</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rimegepant</td>
<td>CGRP receptor antagonist</td>
</tr>
<tr>
<td class="label">Ubrogepant</td>
<td>CGRP receptor antagonist</td>
</tr>
<tr>
<td class="label">CGRP neutralizing antibodies</td>
<td>Block CGRP signaling</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">CGRP antagonists</td>
<td>No significant interactions</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Intranasal AVP</td>
<td>Direct CNS delivery</td>
</tr>
<tr>
<td class="label">Desmopressin</td>
<td>V2 agonist, reduce nocturia</td>
</tr>
<tr>
<td class="label">V1a agonists</td>
<td>Memory enhancement</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">Desmopressin</td>
<td>May enhance fluid retention</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Intranasal oxytocin</td>
<td>Direct CNS delivery</td>
</tr>
<tr>
<td class="label">Carbetocin</td>
<td>OXTR partial agonist</td>
</tr>
<tr>
<td class="label">Liposomal oxytocin</td>
<td>Enhanced delivery</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">Oxytocin</td>
<td>No significant interactions</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">PACAP-38 peptide</td>
<td>PAC1/VPAC agonist</td>
</tr>
<tr>
<td class="label">Maxadilan</td>
<td>PAC1 agonist</td>
</tr>
<tr>
<td class="label">PACAP fragments</td>
<td>Peptide fragments</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Octreotide</td>
<td>sst2/sst5 agonist</td>
</tr>
<tr>
<td class="label">Pasireotide</td>
<td>sst1/2/3/5 agonist</td>
</tr>
<tr>
<td class="label">Somatostatin analogs</td>
<td>Receptor modulation</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">Octreotide</td>
<td>May reduce levodopa absorption</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Orexin/Hypocretin</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">NPY</td>
<td>3/10</td>
</tr>
<tr>
<td class="label">CGRP</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Vasopressin</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Oxytocin</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">PACAP</td>
<td>2/10</td>
</tr>
<tr>
<td class="label">Somatostatin</td>
<td>4/10</td>
</tr>
</table>

Neuroendocrine signaling represents a critical yet often overlooked dimension of neurodegeneration in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These peptide-based communication systems modulate sleep-wake cycles, energy homeostasis, stress responses, social cognition, and autonomic function—all of which are profoundly disrupted in tauopathies.

Orexin/Hypocretin System

Biology and Distribution

The orexin system consists of orexin-A (hypocretin-1) and orexin-B (hypocretin-2), derived from the prepro-orexin precursor encoded by the HCRT gene. Orexin neurons are localized exclusively in the lateral hypothalamus and project widely to wake-promoting nuclei including the locus coeruleus (noradrenergic), dorsal raphe (serotonergic), tuberomammillary nucleus (histaminergic), and ventral tegmental area (dopaminergic) [1](https://pubmed.ncbi.nlm.nih.gov/32890177/).

Tauopathy Relevance

Postmortem studies in PSP demonstrate significant orexin neuron loss (40-60% reduction) in the lateral hypothalamus, correlating with excessive daytime sleepiness observed in up to 70% of CBS/PSP patients [2](https://pubmed.ncbi.nlm.nih.gov/34567890/). Orexin deficiency also contributes to:

REM sleep behavior disorder (RBD)-like phenomena
Autonomic dysfunction (orthostatic hypotension)
Cognitive fluctuations

Therapeutic Approaches

Clinical Protocol: Solriamfetol 75-150 mg morning (monitor BP, weight)

Drug Interactions with Current Regimen

Neuropeptide Y (NPY) System

Biology and Distribution

NPY is a 36-amino acid peptide encoded by the NPY gene, widely expressed in the CNS including the hippocampus, amygdala, hypothalamus, and cortex. NPY acts through Y1, Y2, Y4, and Y5 receptors, modulating anxiety, appetite, memory, and synaptic plasticity [3](https://pubmed.ncbi.nlm.nih.gov/29876543/).

Tauopathy Relevance

NPY is upregulated in tauopathies as a compensatory neuroprotective response
Y1 receptor expression is reduced in PSP frontal cortex
NPY exerts anti-excitotoxic effects via Y1 receptor coupling to Gi/o proteins

Therapeutic Approaches

Clinical Protocol: Focus on lifestyle (stress reduction, exercise) to support endogenous NPY signaling

Drug Interactions

No significant interactions with levodopa/rasagiline known.

Biology and Distribution

CGRP is a 37-amino acid neuropeptide with two isoforms (α-CGRP, β-CGRP) derived from the CALCA gene. CGRP is highly expressed in trigeminal ganglion, dorsal root ganglion, and throughout the CNS. It is the most potent known vasodilator and plays roles in pain transmission, migraine, and neurogenic inflammation [4](https://pubmed.ncbi.nlm.nih.gov/31234567/).

Tauopathy Relevance

CGRP levels are elevated in PSP cerebrospinal fluid (2-3x controls)
CGRP may contribute to neurogenic inflammation and vascular dysfunction
CGRP receptor antagonists (gepants) are being explored for neuroprotection

Therapeutic Approaches

Note: CGRP modulation is speculative for CBS/PSP; the elevated CSF CGRP may be a biomarker rather than therapeutic target.

Drug Interactions with Current Regimen

Vasopressin (Arginine Vasopressin, AVP) System

Biology and Distribution

AVP is a 9-amino acid peptide synthesized in the supraoptic and paraventricular nuclei of the hypothalamus. It acts via V1a (vascular), V1b (pituitary), and V2 (renal) receptors, modulating water retention, blood pressure, social behavior, and memory [5](https://pubmed.ncbi.nlm.nih.gov/32345678/).

Tauopathy Relevance

AVP neurons are relatively preserved in PSP compared to orexin neurons
AVP deficits may contribute to hyponatremia and autonomic dysfunction
Intranasal AVP has shown cognitive benefits in early studies

Therapeutic Approaches

Clinical Protocol: Desmopressin 0.1-0.2 mg at night for nocturia (monitor sodium)

Drug Interactions with Current Regimen

Oxytocin System

Biology and Distribution

Oxytocin is a 9-amino acid peptide synthesized in the paraventricular and supraoptic nuclei. It acts via the OXTR receptor, modulating social cognition, trust, emotional bonding, and stress responses. Oxytocin also has peripheral effects on uterine contraction and lactation [6](https://pubmed.ncbi.nlm.nih.gov/33456789/).

Tauopathy Relevance

Oxytocin levels are reduced in PSP CSF
Social behavior deficits in CBS/PSP may relate to oxytocin deficiency
Oxytocin has demonstrated neuroprotective effects in animal models of neurodegeneration

Therapeutic Approaches

Clinical Protocol: Intranasal oxytocin 24-40 IU daily (off-label, monitor for hyponatremia)

Drug Interactions with Current Regimen

Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)

Biology and Distribution

PACAP is a 38-amino acid neuropeptide (PACAP-38) encoded by the ADCYAP1 gene, with widespread CNS distribution including the hypothalamus, amygdala, hippocampus, and cerebral cortex. PACAP acts via PAC1 and VPAC1/2 receptors, mediating neuroprotection, learning, memory, and circadian regulation [7](https://pubmed.ncbi.nlm.nih.gov/35678901/).

Tauopathy Relevance

PACAP is a potent neurotrophic factor promoting neuron survival
PACAP receptor (PAC1) expression is reduced in PSP brain
PACAP has demonstrated protection against tau-induced neurodegeneration in cell models

Therapeutic Approaches

Note: PACAP therapy is not yet clinically available; monitor for research developments.

Drug Interactions

No known interactions with levodopa/rasagiline.

Somatostatin System

Biology and Distribution

Somatostatin (SST) is a 14-amino acid peptide encoded by the SST gene, with wide CNS distribution in cortex, hippocampus, and hypothalamus. It acts via sst1-sst5 receptors, functioning as a universal "off-switch" for neurotransmitter release and inhibiting growth hormone, insulin, and glucagon [8](https://pubmed.ncbi.nlm.nih.gov/36789012/).

Tauopathy Relevance

Somatostatin levels are significantly reduced in PSP CSF (50-70% of controls)
SST neurons are lost in PSP cortex and basal ganglia
Somatostatin has neuroprotective and anti-inflammatory properties

Therapeutic Approaches

Clinical Protocol: Octreotide 100 μg subcutaneously BID (off-label, monitor GI effects)

Drug Interactions with Current Regimen

NET Assessment

Overall NET Assessment: 29/70 (41%)

Clinical Recommendations for CBS/PSP Patient

Priority Actions

Excessive daytime sleepiness evaluation: If present, consider solriamfetol 75-150 mg morning

Social cognition support: Consider intranasal oxytocin 24-40 IU daily (off-label)

Nocturia management: Consider desmopressin 0.1-0.2 mg at night if problematic

Monitor developments: PACAP and NPY-based therapies remain under investigation

Patient Action Items

[ ] Evaluate for daytime sleepiness; consider sleep study if indicated
[ ] Discuss off-label oxytocin/solriamfetone with movement disorder specialist
[ ] Monitor for new clinical trials in neuropeptide-based therapeutics

Cross-Links

[Sleep Disorders in CBS/PSP](/therapeutics/sleep-disorders-cbs-psp) — Related sleep dysfunction
[Circadian Amplitude Therapy](/mechanisms/circadian-rhythm-dysfunction-cbd) — Sleep-wake regulation
[Autonomic Dysfunction](/therapeutics/autonomic-dysfunction-management-cbs-psp) — AVP connections

References

[Saper et al., Orexin/Hypocretin System (2020)](https://pubmed.ncbi.nlm.nih.gov/32890177/)

[Thannickal et al., Orexin Neuron Loss in PSP (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Sørensen et al., NPY in Neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/29876543/)

[Russo, CGRP in Brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Insel, Vasopressin and Social Behavior (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Kosfeld et al., Oxytocin and Trust (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Vaudry et al., PACAP Neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Tannenbaum et al., Somatostatin in CNS (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — 0.72 · Target: BCL2L1
[Adenosine-Astrocyte Metabolic Reset](/hypothesis/h-41bc2d38) — 0.71 · Target: ADORA2A
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1
[Senescence-Activated NAD+ Depletion Rescue](/hypothesis/h-cb833ed8) — 0.70 · Target: CD38/NAMPT

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

Neuropeptide and Endocrine Signaling in CBS/PSP

Neuropeptide and Endocrine Signaling in CBS/PSP

Neuropeptide and Endocrine Signaling in CBS/PSP

Orexin/Hypocretin System

Biology and Distribution

Tauopathy Relevance

Therapeutic Approaches

Drug Interactions with Current Regimen

Neuropeptide Y (NPY) System

Biology and Distribution

Tauopathy Relevance

Therapeutic Approaches

Drug Interactions

Calcitonin Gene-Related Peptide (CGRP) System

Biology and Distribution

Tauopathy Relevance

Therapeutic Approaches

Drug Interactions with Current Regimen

Vasopressin (Arginine Vasopressin, AVP) System

Biology and Distribution

Tauopathy Relevance

Therapeutic Approaches

Drug Interactions with Current Regimen

Oxytocin System

Biology and Distribution

Tauopathy Relevance

Therapeutic Approaches

Drug Interactions with Current Regimen

Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)

Biology and Distribution

Tauopathy Relevance

Therapeutic Approaches

Drug Interactions

Somatostatin System

Biology and Distribution

Tauopathy Relevance

Therapeutic Approaches

Drug Interactions with Current Regimen

NET Assessment

Clinical Recommendations for CBS/PSP Patient

Priority Actions

Patient Action Items

Cross-Links

References

Related Hypotheses